Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

FDA ‘reset’ continues with new plan for reviewing rare disease drugs

A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one analyst said.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at biopharmadive.com →

More in Health & Medicine

More from Thursday 15 October →